Ipsen Joins PhRMA To Continue Advancing Research And Innovation
– Company meets PhRMA’s new R&D requirements for membership –
– Ipsen CEO David Meek to join PhRMA Board of Directors –
BASKING RIDGE, N.J.--(BUSINESS WIRE)--Ipsen, (Euronext: IPN; ADR: IPSEY) a global biopharmaceutical company, today announced that it has joined the Pharmaceutical Research and Manufacturers of America (PhRMA), one of the most influential industry trade associations in the United States. As a member of PhRMA, Ipsen will gain ongoing access to like-minded industry partners and advocacy organizations at the federal, state and global level, who are equally dedicated to researching and developing new, cutting-edge therapies for patients. Simultaneous to the approval of Ipsen’s membership, Ipsen Chief Executive Officer David Meek will join the Board of Directors of PhRMA.
“We are proud to continue our work with PhRMA, as we are aligned with the organization’s mission of encouraging the discovery of bold new advances in treatments and cures for patients through ongoing partnership and collaboration,” said David Meek, Chief Executive Officer, Ipsen. “Through our research and development efforts, we are continuing to advance treatment options for patients by focusing on scientific innovation and development activities across our core therapeutic areas of oncology, neurosciences and rare disease.”
In May 2017, the PhRMA Board of Directors established new criteria for membership, specifying that biopharmaceutical companies would have to meet new R&D requirements to be eligible to join and/or maintain a membership with PhRMA. These include a three-year average global R&D to global sales ratio of 10 percent or greater and a three-year average global R&D spend of at least $200 million per year. Ipsen Biopharmaceuticals, which had previously been an associate member beginning September 2012, satisfies these new R&D-based criteria.
“We are pleased to welcome Ipsen into our membership. Our members are at the forefront of the most exciting science and research occurring in the biopharmaceutical industry,” said President and Chief Executive Officer of PhRMA Stephen J. UbI. “We look forward to Ipsen’s continued participation in our efforts to advance policies that will help us achieve our goals of modernizing the drug discovery and development process, advancing value-driven health care, ensuring patients benefit more from negotiated discounts and addressing market distorting programs.”
In addition to membership with PhRMA, Ipsen also holds longstanding relationships with a number of associations in North America, including the National Pharmaceutical Council, Organization for International Investment, Innovative Medicines Canada, BioNJ and Massachusetts Biotechnology Council.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone. For information on how innovative medicines save lives, please visit www.PhRMA.org, www.Innovation.org, www.GoBoldly.com, www.Facebook.com/PhRMA or www.Twitter.com/PhRMA.
About Ipsen in North America
Ipsen Biopharmaceuticals, Inc. is the US affiliate of Ipsen, a global specialty-driven biopharmaceutical group. The US head office is located in Basking Ridge, New Jersey. Ipsen Biopharmaceuticals Canada, Inc. is an integrated business unit within North America and has its head office located in Mississauga, Ontario. Ipsen Bioscience, Inc., the Ipsen US research and development center focused on the discovery of highly differentiated and competitive products in oncology and rare diseases, is located in Cambridge, Massachusetts. At Ipsen Bioscience, we focus on creating a highly cooperative and passionate R&D organization through partnerships, innovation, and continuous learning to effectively deliver new treatments for patients. At Ipsen, we focus our resources, investments, and energy on discovering, developing, and commercializing new therapeutic options for oncologic, neurologic, and endocrine diseases. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neurosciences and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales close to €1.6 billion in 2016, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,100 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.